Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCLI Brainstorm Cell Therapeutics	$0.65 +2.3%	$0.91	$0.52 ▼ $5.39	$7.12M	0.12	611,514 shs	17,982 shs
DYAI Dyadic International	$0.85 +8.8%	$0.96	$0.71 ▼ $2.20	$28.26M	0.89	132,437 shs	253,904 shs
MDCX Medicus Pharma	$2.22 -9.4%	$2.67	$1.80 ▼ $8.94	$33.25M	N/A	411,232 shs	590,547 shs
TENX Tenax Therapeutics	$6.00 -0.7%	$5.94	$3.25 ▼ $7.89	$27.56M	1.46	21,375 shs	7,744 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCLI Brainstorm Cell Therapeutics	+2.25%	+3.15%	-5.81%	-40.26%	-88.09%
DYAI Dyadic International	+8.83%	+13.59%	-22.73%	-14.64%	-35.61%
MDCX Medicus Pharma	-9.39%	+13.27%	-27.21%	-69.55%	+221,999,900.00%
TENX Tenax Therapeutics	-0.66%	+0.50%	-0.08%	-0.83%	+42.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCLI Brainstorm Cell Therapeutics	2.3406 of 5 stars	0.0	5.0	4.7	2.1	0.8	0.6
DYAI Dyadic International	3.3385 of 5 stars	3.5	5.0	0.0	2.2	3.3	0.0
MDCX Medicus Pharma	1.8711 of 5 stars	3.8	0.0	0.0	2.2	0.8	0.0
TENX Tenax Therapeutics	1.6216 of 5 stars	3.6	1.0	0.0	1.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCLI Brainstorm Cell Therapeutics	2.00	Hold	N/A	N/A
DYAI Dyadic International	3.00	Buy	$6.00	605.88% Upside
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	958.56% Upside
TENX Tenax Therapeutics	3.25	Buy	$17.00	183.33% Upside

Current Analyst Ratings Breakdown

Latest BCLI, TENX, DYAI, and MDCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
8/14/2025	TENX Tenax Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
8/13/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/23/2025	BCLI Brainstorm Cell Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/1/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/23/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/29/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	($1.36) per share	N/A
DYAI Dyadic International	$3.49M	8.81	N/A	N/A	($0.01) per share	-85.00
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.18 per share	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	$22.65 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCLI Brainstorm Cell Therapeutics	-$11.62M	-$3.10	N/A	N/A	N/A	N/A	N/A	-519.50%	N/A
DYAI Dyadic International	-$5.81M	-$0.19	N/A	N/A	N/A	-134.84%	-355.39%	-60.66%	11/11/2025 (Estimated)
MDCX Medicus Pharma	-$11.16M	-$1.34	N/A	N/A	N/A	N/A	-549.30%	-228.06%	N/A
TENX Tenax Therapeutics	-$17.60M	-$0.92	N/A	N/A	N/A	N/A	-31.34%	-30.39%	N/A

Latest BCLI, TENX, DYAI, and MDCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	DYAI Dyadic International	-$0.06	-$0.06	N/A	-$0.06	$0.60 million	$0.97 million
8/13/2025	Q2 2025	TENX Tenax Therapeutics	-$0.50	-$0.27	+$0.23	-$0.27	N/A	N/A
8/11/2025	Q2 2025	MDCX Medicus Pharma	-$0.39	-$0.43	-$0.04	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCLI Brainstorm Cell Therapeutics	N/A	0.21	0.21
DYAI Dyadic International	5.40	2.02	2.02
MDCX Medicus Pharma	N/A	1.29	1.29
TENX Tenax Therapeutics	N/A	41.89	41.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCLI Brainstorm Cell Therapeutics	14.33%
DYAI Dyadic International	27.95%
MDCX Medicus Pharma	N/A
TENX Tenax Therapeutics	1.67%

Insider Ownership

Company	Insider Ownership
BCLI Brainstorm Cell Therapeutics	11.15%
DYAI Dyadic International	29.50%
MDCX Medicus Pharma	11.20%
TENX Tenax Therapeutics	3.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCLI Brainstorm Cell Therapeutics	40	11.04 million	8.74 million	Optionable
DYAI Dyadic International	7	36.19 million	25.51 million	Optionable
MDCX Medicus Pharma	N/A	13.57 million	12.05 million	N/A
TENX Tenax Therapeutics	9	4.56 million	4.42 million	Not Optionable

BCLI, TENX, DYAI, and MDCX Headlines

Recent News About These Companies

Leerink Partnrs Has Negative Forecast for TENX Q3 Earnings

August 19, 2025 | americanbankingnews.com

William Blair Brokers Decrease Earnings Estimates for TENX

August 19, 2025 | americanbankingnews.com

Q3 EPS Estimate for Tenax Therapeutics Reduced by Analyst

August 18, 2025 | americanbankingnews.com

Equities Analysts Set Expectations for TENX FY2028 Earnings

August 17, 2025 | americanbankingnews.com

Tenax Posts Wider Loss in Fiscal Q2

August 14, 2025 | aol.comA

Tenax Therapeutics reports Q2 EPS (27c), consensus (45c)

August 14, 2025 | msn.com

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | globenewswire.com

TENX Tenax Therapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | globenewswire.com

Tenax Therapeutics Inc.

May 9, 2025 | barrons.com

Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts

April 16, 2025 | seekingalpha.com

Tenax Therapeutics files to sell 4.14M shares of common stock for holders

April 16, 2025 | markets.businessinsider.com

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025 | globenewswire.com

Tenax Therapeutics reports Q4 EPS (18c), consensus (43c)

March 27, 2025 | markets.businessinsider.com

Tenax Therapeutics (TENX) Gets a Buy from William Blair

March 27, 2025 | markets.businessinsider.com

Tenax Therapeutics: Q4 Earnings Snapshot

March 25, 2025 | timesunion.comT

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 25, 2025 | globenewswire.com

Tenax Therapeutics Inc TENX

March 14, 2025 | morningstar.comM

Roth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)

March 6, 2025 | markets.businessinsider.com

Tenax Therapeutics expands Phase 3 LEVEL program for TNX-103

March 5, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI, TENX, DYAI, and MDCX Company Descriptions

Brainstorm Cell Therapeutics NASDAQ:BCLI

$0.65 +0.01 (+2.25%)

As of 08/22/2025 03:21 PM Eastern

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Dyadic International NASDAQ:DYAI

$0.85 +0.07 (+8.83%)

As of 08/22/2025 04:00 PM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Medicus Pharma NASDAQ:MDCX

$2.22 -0.23 (-9.39%)

As of 08/22/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Tenax Therapeutics NASDAQ:TENX

$6.00 -0.04 (-0.66%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.86 -0.14 (-2.25%)

As of 08/22/2025 06:57 PM Eastern

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time